-
Deutsche Bank Updates 8/8
Monday, August 8, 2011 - 6:42am | 535Deutsche Bank made a number of updates in a research report published today. Magna International (NYSE: MGA) had its rating reiterated at Hold. At the same time, its price target was reduced from $57 to $55. On Friday, MGA lost 10.92% of its value to end the day at $39.42....
-
Deutsche Bank Lowers PT on Nektar Therapeutics to $11
Monday, August 8, 2011 - 6:22am | 27Deutsche Bank has lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) from $14 to $11 and maintains its Buy rating.
-
Earnings Scheduled For August 8
Monday, August 8, 2011 - 3:50am | 413Dollar Thrifty Automotive Group Inc (NYSE: DTG) is projected to report its Q2 EPS at $1.37 on revenue of $408.57 million. MGM Resorts International (NYSE: MGM) is projected to report a FQ4 loss at $0.13 per share on revenue of $1.59 billion. 99 Cents Only Stores (NYSE: NDN) is expected to...
-
Options Brief: Pharmaceutical Product Development
Friday, August 5, 2011 - 1:23pm | 81Shares of Pharmaceutical Product Development (NASDAQ: PPDI) are higher on the session by 0.39%, trading at $26.89. Overall put volume is now running at 14.89x the daily average, with 100% of all puts traded being purchases on the offer. 2,010 contracts have traded on the session so far....
-
Rodman & Renshaw Maintains Sequenom Market Perform
Friday, August 5, 2011 - 11:37am | 103Rodman & Renshaw maintained its Sequenom (NASDAQ: SQNM) Market Perform rating in a research report published today. In the report, Rodman & Renshaw states, "The company has selected MaterniT21 as the brand name for its proprietary T21 LDT, and is expected to launch the test in late 2011 or...
-
A Peek Into The Market Before The Trading Starts
Friday, August 5, 2011 - 7:27am | 404Pre-open movers US stock futures are lower this morning, as investors are awaiting employment data. Futures for the Dow Jones Industrial Average dipped 35 points to 11,336.00 and S&P 500 index futures fell 2.20 points to 1,196.50. Nasdaq 100 futures dropped 7.50 points to 2,202.00. A Peek...
-
QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer
Friday, August 5, 2011 - 6:56am | 147QIAGEN (NASDAQ: QGEN) today announced it has completed its second U.S. submission of the therascreen KRAS RGQ PCR Kit for use as a companion diagnostic paired with Erbitux (cetuximab). Erbitux is marketed in the United States by Bristol-Myers Squibb Company and Eli Lilly and Company. Merck KGaA has...
-
Jefferies Rating and PT Updates 8/4
Thursday, August 4, 2011 - 8:12am | 1311Jefferies made a number of rating and price target changes in a research report published today. AstraZeneca PLC (NYSE: AZN) had its rating upgraded from Underperform to Hold. On Wednesday, AZN lost 0.34% of its value to finish the day at $47. Its shares continued to slide in today's pre-market...
-
Medivation and Astellas Announce New Preclinical Study Results Showing MDV3100 Blocks Breast Cancer Cell Growth
Thursday, August 4, 2011 - 8:10am | 81Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced results from a preclinical study conducted by researchers at the University of Colorado Denver that provide evidence that MDV3100 inhibits proliferation of breast cancer cells. In different cell-based assays, MDV3100 was able...
-
J.P. Morgan Maintains Overweight on Illumina
Wednesday, August 3, 2011 - 8:54am | 79J.P. Morgan is out with its report today on Illumina (NASDAQ: ILMN), maintaining Overweight. In its report, J.P. Morgan writes, "We see potential upside to 2011 and 2012 consensus estimates given conservative management guidance and the MiSeq launch; longer-term risks (e.g., NGS saturation,...
-
Last Nights Headlines, Morning Action August 3
Wednesday, August 3, 2011 - 8:37am | 294AM Action: (GLD), (SLV) Up on the overnight session and off highs after a better than expected ADP report (ILMN) Illumina Inc. 100 million repurchase Peet's Coffee (PEET) Ttarget raised to $72 from $60 at Stifel Nicolaus Micro Strategy (MSTR) Off 15 points pre market on a bad miss Last Nights...
-
Wedbush Raises PT on Caliper Life Sciences To $10
Wednesday, August 3, 2011 - 8:26am | 28Wedbush Securities has raised the price target on Caliper Life Sciences (NASDAQ: CALP) from $9 to $10 and maintains its Outperform rating.
-
Jefferies Comments On Bio-Rad Laboratories 2Q11 EPS
Wednesday, August 3, 2011 - 8:19am | 86According to Jefferies, Bio-Rad Laboratories (NYSE: BIO) reaffirmed its formal 2011 organic revenue growth outlook of ~5%. Jefferies said that adjusted 2Q11 EPS of $1.41 was $0.06 below consensus as a higher tax rate (-$0.07) offset a better than expected revenue growth experience. The 2011 EPS...
-
MSMB Capital Proposes Acquisition of Amag Pharmaceuticals for $18 Per Share
Wednesday, August 3, 2011 - 7:19am | 82MSMB Capital Management today announced that it has made a proposal to the Board of Directors of Amag Pharmaceuticals Inc. (NASDAQ: AMAG) to acquire all of the outstanding shares of common stock of Amag for $18 per share in cash or an aggregate of $378 million. This proposal represents an...
-
Illumina Announces New $100 Million Share Repurchase Authorization
Wednesday, August 3, 2011 - 7:09am | 67Illumina (Nasdaq: ILMN) today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and...